Dr. Goldstein is a pharmacologist and neuroscientist whose career has been devoted mainly to research on addictive drugs -- primarily the opiates, the opioid peptides, and their receptors. For 34 years until 1989 he was at Stanford University as director of the Addiction Research Foundation at Palo Alto.
His laboratory research laid the basis for studying the opiate receptors, and he discovered one of the three families of opioid peptides -- the dynorphins.
He established the first methadone program in California, in San Jose. There, and later at the Addiction Research Foundation, he and his colleagues contributed important research findings on the use of methadone, LAAM, and naltrexone in the treatment of heroin addicts. He also played a key role in the development of rapid and efficient on-site urine tests for illicit drug use.
Dr. Goldstein has published more than 360 research papers, and is author of three books -- Biostatistics: An Introductory Text (1964), Principles of Drug Action (a basic textbook of pharmacology; 1968, 1974), and Addiction: From Biology to Drug policy (1994).
A member of the National Academy of Sciences (recently chairman of the Section of Physiology and Pharmacology) and also of its Institute of Medicine, he is a recipient of many awards including the Franklin Medal, Nathan B.Eddy Award, and Sollmann Award. He served two terms on the National Advisory Council of the National Institute on Drug Abuse. He is an honorary professor of the Beijing Medical University and of the Institute of Materia Medica of the Academia Sinica. Formerly scientific advisor to the Syva Company, the DNAX Research Institute, Receptron, Inc., and Abbott Laboratories, he is presently a consultant to Receptron, Inc., Neurobiological Technologies, Inc. and the drug discovery company Affymax, N.V. (of which he is a Founder Scientist).